Shares of ReWalk Robotics Ltd. (NASDAQ:RWLK) dropped 2.5% during trading on Thursday . The company traded as low as $6.61 and last traded at $6.68, with a volume of 114,324 shares trading hands. The stock had previously closed at $6.85.

RWLK has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of ReWalk Robotics from a “sell” rating to a “hold” rating in a research note on Thursday, April 28th. Jefferies Group restated a “buy” rating and set a $16.00 price target on shares of ReWalk Robotics in a research note on Sunday, May 8th. Piper Jaffray Cos. initiated coverage on shares of ReWalk Robotics in a research note on Friday, July 15th. They set an “overweight” rating and a $10.00 price target on the stock. Finally, Canaccord Genuity restated a “buy” rating on shares of ReWalk Robotics in a research note on Sunday, August 7th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $12.80.

The company’s 50 day moving average price is $6.68 and its 200 day moving average price is $8.44. The firm’s market cap is $82.38 million.

ReWalk Robotics (NASDAQ:RWLK) last issued its quarterly earnings results on Thursday, August 4th. The medical device company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.11. The company had revenue of $0.82 million for the quarter, compared to the consensus estimate of $1.95 million. ReWalk Robotics’s revenue for the quarter was up 34.4% compared to the same quarter last year. On average, equities analysts predict that ReWalk Robotics Ltd. will post ($2.34) earnings per share for the current fiscal year.

In other ReWalk Robotics news, major shareholder Scp Vitalife Partners (Israel) sold 4,043 shares of the firm’s stock in a transaction dated Friday, May 20th. The shares were sold at an average price of $9.09, for a total transaction of $36,750.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeff Dykan sold 27,022 shares of the firm’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $8.69, for a total transaction of $234,821.18. The disclosure for this sale can be found here.

ReWalk Robotics Ltd. is a medical device company. The Company is engaged in designing, developing and commercializing exoskeletons that allow wheelchair-bound individuals with mobility impairments or other medical conditions the ability to stand and walk. The Company offers ReWalk, an exoskeleton that uses its tilt-sensor technology, and an on-board computer and motion sensors to drive motorized legs that power movement.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.